FDA approves Procysbi for nephropathic cystinosis

FDA approves procysbi for nephropathic cystinosis
Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended to treat a rare disease or condition, Procysbi has been granted orphan product designation.

(HealthDay)—Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended to treat a rare disease or condition, Procysbi has been granted orphan product designation.

Affecting approximately 500 patients in the United States and an estimated 3,000 worldwide, cystinosis can lead to slow body growth and small stature, weak bones, and developing and worsening . Procysbi has been approved to treat the most severe form of cystinosis—nephropathic cystinosis.

A major study involving 43 patients found Procysbi to be as effective at controlling cystine levels as Cystagon, an immediate-release tablet approved by the FDA in 1994. Recorded common side effects included gastrointestinal discomfit, bad breath, constipation, headache, drowsiness, and dizziness. More severe but less common side effects included ulcers or bleeding of the stomach or intestine, altered mental state, seizures, severe skin rashes, and allergic reactions.

"Procysbi is the only delayed-release product approved by FDA to treat nephropathic cystinosis, offering patients with this an important new treatment option," Andrew E. Mulberg, M.D., deputy director of the Division of Gastroenterology and Inborn Errors Products in the FDA's Center for and Research, said in a statement.

Procysbi is manufactured by Raptor Pharmaceuticals, based in Novato, Calif.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

FDA OKs drug to treat bleeding disorder

Apr 30, 2007

The U.S. Food and Drug Administration has approved Humate-P for the treatment of a specific bleeding disorder called von Willebrand disease.

Iclusig approved for rare leukemias

Dec 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Recommended for you

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

Flu vaccine for expectant moms a top priority

Sep 18, 2014

Only about half of all pregnant women in the U.S. get a flu shot each season, leaving thousands of moms-to-be and their babies at increased risk of serious illness.

Experts want restrictions on testosterone drug use (Update)

Sep 17, 2014

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

User comments